Ethinylestradiol/etonogestrel vaginal

Drug Profile

Ethinylestradiol/etonogestrel vaginal

Alternative Names: Etonogestrel/ethinylestradiol; NuvaRing; SCH-900702

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Organon
  • Developer Merck & Co
  • Class Alkylated estrogenic steroids; Hormonal contraceptives; Norpregnanes; Norpregnatrienes; Progesterone congeners
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Contraception

Most Recent Events

  • 09 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Argentina, Singapore, Thailand, Hungary and New Zealand (Vaginal) prior to February 2015
  • 01 Sep 2013 Merck completes a phase III trial in Contraception/Pregnancy (Prevention) in China (NCT01277211)
  • 09 Aug 2012 Merck completes enrolment in its phase III trial for Contraception/Pregnancy (Prevention) in China (NCT01277211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top